| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Additional conditions recognized in this trial | ||||
| Central Nervous System Neoplasms | |||||
| Glioma | |||||
| Nervous System Neoplasms | |||||
| 2 | More general conditions related to this trial | ||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms by Site | |||||
| Neoplasms, Germ Cell and Embryonal | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Neoplasms, Nerve Tissue | |||||
| Neoplasms, Neuroepithelial | |||||
| Nervous System Diseases | |||||
| Neuroectodermal Tumors | |||||
| 3 | Interventions listed in this trial | ||||
| temozolomide | |||||
| 4 | More general drug interventions related to this trial | ||||
| Alkylating Agents | |||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Alkylating | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 5 | Sponsors listed in this trial | ||||
| Duke University | |||||
| National Cancer Institute (NCI) | |||||
|
